|
AMPHOTERICIN B INCREASES PLASMA CONCENTRATION OF THE DRUG
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED RISK OF BONE MARROW SUPPRESSION
|
INCREASED CHANCES OF PERIPHERAL NEUROPATHY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR DRUG-INDUCED RENAL TOXICITY
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
CONCURRENT USE MAY CAUSE / POTENTIATE HYPOKALEMIA WHICH COULD PREDISPOSE THE PATIENT TO CARDIAC DYSFUNCTION
|
AMPHOTERICIN B INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL RELAXANTS
|
AMPHOTERICIN B INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL RELAXANTS
|
AMPHOTERICIN B INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL RELAXANTS
|
AMPHOTERICIN B INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL RELAXANTS
|
AMPHOTERICIN B INDUCED HYPOKALEMIA MAY ENHANCE THE CURARIFORM EFFECT OF SKELETAL RELAXANTS
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
CONCURRENT USE MAY ENHANCE THE POTENTIAL FOR RENAL TOXICITY, BRONCHOSPASM, AND HYPOTENSION
|
ANTOGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
CONCURRENT INITIATION OF CYCLOSPORINE AND ABELCET WITHIN SEVERAL DAYS OF BONE MARROW ABLATION MAY BE ASSOCIATED WITH INCREASED NEPHROTOXICITY
|
CONCURRENT USE MAY INDUCE HYPOKALEMIA AND MAY POTENTIATE DIGITALIS TOXICITY
|
CONCURRENT USE MAY INDUCE HYPOKALEMIA AND MAY POTENTIATE DIGITALIS TOXICITY
|
ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
ANTAGONISM BETWEEN AMPHOTERICIN B AND IMIDAZOLE DERIVATIVES, WHICH INHIBIT ERGOSTEROL SYNTHESIS, HAS BEEN REPORTED ; CLINICAL SIGNIFICANCE OF THIS FINDING HAS NOT BEEN DETERMINED
|
|
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|